Active Ingredient History
Eltrombopag is a thrombopoietin (TPO) nonpeptide mimetic administered orally that activates the TPO receptor by binding to the transmembrane domain and initiates signaling cascades that induce proliferation and differentiation of megakaryocytes from bone marrow progenitor cells. Eltrombopag under brand name promacta is approved for the treatment of the low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood. Eltrombopag has also been approved for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy and to treat patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Acute-On-Chronic Liver Failure (Phase 3)
Acute Radiation Syndrome (Phase 1)
Allografts (Phase 3)
Anemia (Phase 2)
Anemia, Aplastic (Phase 4)
Anemia, Diamond-Blackfan (Phase 1/Phase 2)
Anemia, Hemolytic, Autoimmune (Phase 4)
Autoantibodies (Phase 4)
Blood Platelet Disorders (Phase 2)
Bone Marrow Failure Disorders (Phase 2)
Bone Marrow Transplantation (Phase 2)
Connective Tissue Diseases (Phase 4)
Cord Blood Stem Cell Transplantation (Phase 2)
Drugs, Investigational (Phase 4)
Fanconi Anemia (Phase 2)
Healthy Volunteers (Phase 1)
Hematologic Neoplasms (Phase 4)
Hematopoietic Stem Cell Transplantation (Phase 3)
Hemorrhage (Phase 2)
Hepacivirus (Phase 3)
Hepatitis B (Phase 3)
Hepatitis B virus (Phase 3)
Hepatitis C (Phase 3)
Hepatitis C, Chronic (Phase 3)
HIV (Phase 3)
HIV Infections (Phase 3)
Leukemia (Phase 2)
Leukemia, Eosinophilic, Acute (Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Leukemia, Monocytic, Acute (Phase 2)
Leukemia, Myeloid, Acute (Phase 2/Phase 3)
Leukemia, Myeloid, Chronic-Phase (Phase 2)
Leukemia, Myelomonocytic, Acute (Phase 2)
Leukemia, Myelomonocytic, Chronic (Phase 2)
Liver Cirrhosis (Phase 1)
Liver Diseases (Phase 3)
Lymphoma, B-Cell (Phase 2)
Lymphoma, B-Cell, Marginal Zone (Phase 2)
Lymphoma, Follicular (Phase 2)
Lymphoma, Mantle-Cell (Phase 2)
Lymphoma, Non-Hodgkin (Phase 2)
Multiple Myeloma (Phase 2)
Myelodysplastic Syndromes (Phase 2)
Neoplasms (Phase 3)
Neoplasms, Connective and Soft Tissue (Phase 1)
Non-alcoholic Fatty Liver Disease (Phase 3)
Osteosarcoma (Phase 1)
Pancytopenia (Phase 2)
Primary Myelofibrosis (Phase 2)
Purpura (Phase 4)
Purpura, Thrombocytopenic, Idiopathic (Phase 4)
Sarcoma (Phase 1)
Therapeutics (Phase 2)
Thrombocytopenia (Phase 4)
Wiskott-Aldrich Syndrome (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
